MPCCC Precision Oncology Program Launch: Professor Melissa Southey

In October 2020, the Monash Partners Comprehensive Cancer Consortium (MPCCC) launched its Precision Oncology Program.

This program brings together expert cancer researchers and clinicians from across MPCCC's partner health services and research institutes to respond to the treatment needs of patients with rare, advanced stage, and therapy-resistant cancers.

The MPCCC Precision Oncology Program co-ordinates referrals for molecular profiling from oncologists at its partner health services to an Australian research study, and provides support to interpret the results in the form of Molecular tumour Board (MTB) meetings to support them guiding patient treatment and care.